Clinical trials: Hodgkin Disease Refractory
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with…
- Trial name
- NCT04875195
- Testing
- Pembrolizumab
- Where
- 27 sites in United States, Brazil and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
B-NHL
An Evaluation of LY007 Cell Injection for r/r B-NHL
An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research
- Trial name
- r/r B-NHL (NCT06279611)
- Testing
- LY007
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Longyao Biotechnology Inc., Ltd.
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Lymphoma, Lymphoma, Non-Hodgkin
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT02690545
- Testing
- ATLCAR.CD30 cells
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma
INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma
A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.
- Trial name
- NCT02456675
- Testing
- INCB040093 Monotherapy, INCB040093, itacitinib
- Volunteers
- 8 people
- Sponsor
- Incyte Corporation
Celiac Disease
Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease
Video capsule endoscopy (VCE) is recommended as the gold standard in small bowel exploration. The efficiency of the axial-viewing (Given, Imaging) has been widely reported.
- Trial name
- NCT03095573
- Testing
- Lateral-viewing CapsoCam device, Axial-viewing capsule
- Where
- 2 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
This phase I trial studies the side effects and best dose of pomalidomide when given together with dexamethasone in treating patients with primary central nervous system lymphoma that has come back (relapsed) or does not respond…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
- Trial name
- NCT01722305
- Testing
- Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
The purpose of this study is to evaluate the safety and efficiency of autologous CD19 CAR-T lymphocytes in a cohort of pediatric and young adult patients with relapsed /refractory B-lineage acute lymphoblastic leukemia
- Trial name
- NCT03467256
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Fludarabine, Cyclophosphamide
- Where
- Russia
- Volunteers
- 18 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
Chimeric antigen receptor-modified T cells (CART) holds great promise for treatment of tumors. In this trial, CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma will be treated by CD30-specific CART cells (CART30).
- Trial name
- CART30 (NCT02259556)
- Testing
- CART30
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Relapsed or Refractory B Cell Non Hodgkin Lymphoma
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT06970496
- Testing
- B019
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat…
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT06458439
- Testing
- Epcoritamab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Hodgkin's Lymphoma
Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory
PET-based consolidation and donor-based therapy after rescue in patients with Hodgkin's lymphoma refractory at first line therapy, or relapse early or late, undergone a second line chemotherapy.
- Trial name
- NCT00879528
- Testing
- Patients with negative PET after salvage therapy, Patients with positive PET after salvage therapy
- Where
- 39 sites in Italy
- Volunteers
- 264 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.
- Trial name
- NCT05883709
- Testing
- Tafasitamab Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhao Weili
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has…
- Trial name
- NCT07003295
- Testing
- Biospecimen Collection, Computed Tomography, Glofitamab
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma (NHL)
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.
- Trial name
- NCT07888530
- Testing
- Ranicabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
This phase I trial studies the side effects and best dose of alisertib and romidepsin in treating patients with B-cell or T-cell lymphomas that have returned after a period of improvement (relapsed) or have not responded to…
- Conditions
- MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01897012
- Testing
- Alisertib, Laboratory Biomarker Analysis, Romidepsin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkins Lymphoma
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
- Trial name
- NCT00054834
- Testing
- hLL2 (epratuzumab)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.